FMI opines that the Exosome-Based Neurodegenerative Disease Therapeutics Market was valued at USD 25.9 million in 2025. The industry is expected to reach USD 32.8 million in 2026. Mesenchymal stem cell-derived exosomes are poised to lead by Exosome source/platform with 49.0% share in 2026, and Alzheimer’s disease is estimated to dominate by Indication through 2036.